DiscoveryProbe™ FDA-approved Drug Library: Mechanisms, Evidence, and Screening Applications

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 clinically approved compounds, supporting high-throughput and high-content screening workflows (APExBIO). It covers a broad spectrum of mechanisms, including enzyme inhibition, receptor modulation, and ion channel regulation. The library’s pre-dissolved, stable 10 mM DMSO format enables robust, reproducible drug repositioning and pharmacological target identification. Compounds such as doxorubicin and metformin are included, facilitating translational research in oncology and neurodegenerative disorders (Song et al., 2023). It offers 12–24 months stability at -20°C to -80°C and is distributed in formats optimal for HTS and HCS platforms.

Biological Rationale

The demand for rapid drug discovery and repositioning has increased with the complexity and heterogeneity of diseases such as cancer and neurodegenerative disorders (Song et al., 2023). Screening libraries composed of FDA-approved and globally sanctioned drugs provide a head start in safety and pharmacokinetics. These compounds have well-characterized mechanisms, making them ideal for elucidating biological pathways, mechanisms of action, and off-target effects. Drug repositioning leverages existing safety data to accelerate clinical translation. Libraries such as the DiscoveryProbe™ FDA-approved Drug Library allow systematic, scalable screening for new indications, target validation, and pathway interrogation, reducing attrition in preclinical and clinical development (internal article).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

This compound library encompasses a wide array of pharmacological classes:

• Receptor agonists and antagonists: e.g., beta-blockers, opioid antagonists
• Enzyme inhibitors: e.g., HDAC inhibitors such as vorinostat, kinase inhibitors
• Ion channel modulators: e.g., calcium channel blockers, sodium channel inhibitors
• Signal pathway regulators: e.g., mTOR, PI3K, and JAK-STAT pathway modulators

Each compound is supplied as a 10 mM DMSO solution, facilitating direct addition to cell-based or biochemical assays. The collection supports interrogation of diverse signaling pathways and cellular phenotypes. For example, carbenoxolone disodium, included in the library, was shown to inhibit HDAC6 (IC₅₀ = 0.772 μM) and suppress gastric cancer cell migration (Song et al., 2023).

Evidence & Benchmarks

• Carbenoxolone disodium, part of the DiscoveryProbe™ FDA-approved Drug Library, inhibits HDAC6 with an IC₅₀ of 0.772 μM and a K_D of 0.943 μM, demonstrating direct target engagement (Song et al., DOI).
• In vivo and in vitro studies confirm that carbenoxolone disodium reduces migration and proliferation of gastric cancer cells (MGC-803), supporting its utility for anti-cancer screens (Song et al., DOI).
• HDAC inhibition by library compounds has been linked to modulation of epigenetic states and tumor suppressor pathways, facilitating target validation (Song et al., DOI).
• The DiscoveryProbe™ library’s pre-dissolved format ensures consistency and minimizes pipetting error, supporting high-content and high-throughput screening reproducibility (APExBIO).

This article extends findings from "DiscoveryProbe FDA-approved Drug Library: Powering High-Throughput Drug Discovery" by providing detailed mechanistic insight and benchmarking with peer-reviewed data.

Applications, Limits & Misconceptions

Research Applications

• Drug Repositioning Screening: Rapid identification of new indications for approved drugs (see internal article).
• Pharmacological Target Identification: Deconvolution of phenotypic screening hits using known compound-target annotations.
• Cancer Research Drug Screening: Application in cell-based and in vivo models for oncology target discovery.
• Neurodegenerative Disease Drug Discovery: Screening for neuroprotective or pathway-modulating agents.
• Signal Pathway Regulation: Interrogation of major signaling axes—e.g., HDAC, mTOR, EGFR pathways.

This article clarifies the mechanistic breadth of the DiscoveryProbe™ library, complementing the workflow-focused overview in "DiscoveryProbe FDA-approved Drug Library: High-Impact Screening".

Common Pitfalls or Misconceptions

• The library is not a substitute for de novo drug design; it is limited to known, approved molecules.
• Not all compounds are equally potent in all assay systems; context-dependent validation is essential.
• Compounds are provided in DMSO; some biological systems may be DMSO-sensitive.
• Off-target effects are possible; follow-up validation is required to confirm specificity.
• Stability is guaranteed only under specified storage conditions (-20°C to -80°C); improper handling can affect compound integrity.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is available in 96-well, deep-well, and 2D barcoded tube formats. Each compound is pre-dissolved at 10 mM in DMSO, supporting rapid, error-minimized dispensing. Recommended storage is -20°C for up to 12 months or -80°C for up to 24 months. Blue ice shipping preserves stability for evaluation samples; room temperature or blue ice options are available for larger shipments. The library is compatible with high-throughput and high-content screening (HTS/HCS) platforms and supports downstream hit validation workflows. Its robust curation and clinical annotation facilitate data integration and interpretation in translational research (see translational acceleration article—this article provides mechanistic and benchmarking details).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO offers a rigorously curated, clinically annotated collection of approved drugs in a workflow-ready format. It enables efficient drug repositioning, pharmacological target identification, and mechanistic screening across multiple disease areas. Peer-reviewed evidence demonstrates its value in oncology and epigenetic research. Proper use and integration into validated screening workflows can accelerate therapeutic discovery and translational research. For further details and ordering information, visit the DiscoveryProbe™ FDA-approved Drug Library product page.